Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 3/20 | 0.48 |
| ▸ | SYK | P43405 | 13/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010274 | 0.93 | GFER (0.49) | STAT6GFERSYKGAAMAPT | |
| SCHEMBL17021296 | 0.92 | STAT6 (0.47) | STAT6SYKMAPTMAPK1MEN1 | |
| SCHEMBL17021388 | 0.91 | STAT6 (0.49) | STAT6GFERSYKGAAMAPT | |
| SCHEMBL17021293 | 0.89 | JAK2 (0.50) | STAT6GFERSYKJAK2JAK1 | |
| SCHEMBL17021387 | 0.88 | STAT6 (0.51) | STAT6GFERSYKGAAMAPT | |
| SCHEMBL17009127 | 0.88 | MAPT (0.61) | STAT6GFERSYKGAAMAPT | |
| SCHEMBL2696460 | 0.86 | STAT6 (0.57) | STAT6SYKJAK2JAK1TYK2 | |
| SCHEMBL17021275 | 0.86 | GAA (0.52) | STAT6GFERSYKGAAMAPT | |
| SCHEMBL17021378 | 0.86 | CYP17A1 (0.42) | STAT6GFERSYKGAAMAPT | |
| SCHEMBL19010277 | 0.86 | KMT2A (0.44) | STAT6GFERSYKGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| WO-2015123453-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015123453-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | STAT6 8/4885GFER 3845/4885SYK 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.